Literature DB >> 1141437

A molecular defect in thrombasthenic platelets.

L Degos, A Dautigny, J C Brouet, M Colombani, N Ardaillou, J P Caen, J Colombani.   

Abstract

An IgG antibody found in the serum of a thrombasthenic patient reacted in complement fixation with platelets from 350 normal individuals but was nonreactive with platelets from eight other thrombasthenic patients. ADP-induced aggregation of normal platelets was inhibited by the patient's antibody. Family studies using the quantitative complement fixation test showed that healthy heterozygotes were easily distinguishable from normal or thrombasthenic individuals since their platelets had an intermediate amount of the reactive antigen. Indirect immunoprecipitation tests using this serum and soluble membrane antigens labeled with iodine-125 that had been extracted from normal platelets by the detergent Nonidet P-40 gave a single radioactive peak at 120,000 mol wt in sodium dodecyl sulfate polyacrylamide gel electrophoresis. A similar estimate of the molecular weight was obtained from Sephadex G-200 filtration of the soluble antigens extracted from normal platelets by spontaneous release or chaotropic agents and tested in complement fixation with the patient's serum. These findings strongly suggest that the molecule recognized by this antibody is absent or structurally modified in thrombasthenia cases and that it may be involved in platelet aggregation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1141437      PMCID: PMC436575          DOI: 10.1172/JCI108074

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  Human erythrocyte membrane glycoprotein: a re-evaluation of the molecular weight as determined by SDS polyacrylamide gel electrophoresis.

Authors:  J P Segrest; R L Jackson; E P Andrews; V T Marchesi
Journal:  Biochem Biophys Res Commun       Date:  1971-07-16       Impact factor: 3.575

2.  International agreement on a microtechnique of platelet complement fixation (Pl. C fix.).

Authors:  J Colombani; J D'Amaro; B Gabb; G Smith; A Svejgaard
Journal:  Transplant Proc       Date:  1971-03       Impact factor: 1.066

3.  An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia.

Authors:  A T Nurden; J P Caen
Journal:  Br J Haematol       Date:  1974-10       Impact factor: 6.998

4.  Non-complement-fixing IgM antibodies with anti-HL-A2 specificity and blocking activity.

Authors:  J Colombani; M Colombani; J Dausset
Journal:  Transplantation       Date:  1973-09       Impact factor: 4.939

5.  Purification and characterization of HL-A antigens from human platelets, solubilized by the non-ionic detergent NP-40.

Authors:  A Dautigny; I Bernier; J Colombani; P Jollés
Journal:  Biochim Biophys Acta       Date:  1973-04-16

6.  Platelet transfusions: shortened survival of HL-A-identical platelets and failure of in vitro detection of anti-platelet antibodies after multiple transfusions.

Authors:  U Bucher; A de Weck; H Spengler; L Tschopp; H Kummer
Journal:  Vox Sang       Date:  1973       Impact factor: 2.144

7.  Effect of trypsin on the exposed polypeptides and glycoproteins in the human platelet membrane.

Authors:  D R Phillips
Journal:  Biochemistry       Date:  1972-11-21       Impact factor: 3.162

8.  Studies on the proteins of human platelet membranes.

Authors:  R L Nachman; B Ferris
Journal:  J Biol Chem       Date:  1972-07-25       Impact factor: 5.157

9.  Isolation of H-2 alloantigens solubilized by the detergent NP-40.

Authors:  B D Schwartz; S G Nathenson
Journal:  J Immunol       Date:  1971-11       Impact factor: 5.422

10.  An enzymic method for the trace iodination of immunoglobulins and other proteins.

Authors:  J J Marchalonis
Journal:  Biochem J       Date:  1969-06       Impact factor: 3.857

View more
  13 in total

1.  On the association of the platelet-specific alloantigen, Pena, with glycoprotein IIIa. Evidence for heterogeneity of glycoprotein IIIa.

Authors:  K Furihata; D J Nugent; A Bissonette; R H Aster; T J Kunicki
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

2.  Assignment of human platelet GP2B (GPIIb) gene to chromosome 17, region q21.1-q21.3.

Authors:  N V Cong; G Uzan; M S Gross; C Jegou-Foubert; P Frachet; C Boucheix; G Marguerie; J Frézal
Journal:  Hum Genet       Date:  1988-12       Impact factor: 4.132

3.  Renal embolisation in Glanzmann's thrombasthenia.

Authors:  E Briët; F J Vismans; A E van Voorthuisen
Journal:  Br Med J       Date:  1980-10-18

4.  Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen.

Authors:  R L Nachman; L L Leung
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

5.  A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.

Authors:  B S Coller; E I Peerschke; L E Scudder; C A Sullivan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

6.  Identification of the thrombin receptor on human platelets by chemical crosslinking.

Authors:  J Takamatsu; M K Horne; H R Gralnick
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

7.  Exposure of platelet fibrinogen receptors by ADP and epinephrine.

Authors:  J S Bennett; G Vilaire
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

8.  Inheritance of the human platelet alloantigen, PlA1, in type I Glanzmann's thrombasthenia.

Authors:  T J Kunicki; D Pidard; J P Cazenave; A T Nurden; J P Caen
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

9.  Isolation and quantitation of the platelet membrane glycoprotein deficient in thrombasthenia using a monoclonal hybridoma antibody.

Authors:  R P McEver; N L Baenziger; P W Majerus
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

10.  Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann's thrombasthenia and Bernard-Soulier syndrome.

Authors:  I Hagen; A Nurden; O J Bjerrum; N O Solum; J Caen
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.